Zagazig University Hospitals, Zagazig, Egypt.
University of Central Florida College of Medicine, Graduate Medical Education, Florida, USA.
BMC Cardiovasc Disord. 2024 Mar 13;24(1):152. doi: 10.1186/s12872-024-03785-3.
Hypertension may cause target organ damage (TOD). Target blood pressure (BP) management may not be appropriate in some conditions.
We aim to assess the impact of targeted BP management in severe hypertension on renal TOD.
PATIENTS & METHODS: This is a prospective cohort study involving patients admitted due to severe hypertension (BP > 180/120) associated with any symptoms. The study involved patients referred to the ICU in our tertiary center during the period between August 2017 and February 2018. All patients underwent target BP treatment according to recent guidelines. Hs-Troponin T (hs-TNT) and serum creatinine (s.creat) were measured in all patients on admission and 24 h later. Patients were divided into Group A (with initial normal hs-TNT) and Group B (with initial high hs-TNT). The main outcome was in-hospital renal-related morbidity (including renal failure).
Four hundred seventy consecutive patients with hypertensive crises were involved in the study. Group B had a significantly higher incidence of in-hospital mortality (4 patients) and renal TOD (acute renal dysfunction) than Group A (P value = 0.001 and 0.000 respectively). There was a significant difference between initial s.creat on admission and follow-up s.creat values in Group B with significant elevation of their s.creat on the following 24 h (P = 0.002), while this difference is insignificant in Group A (P = 0.34). There was a significant positive correlation between hs-TNT and the follow-up s.creat (P = 0.004).
In severe HTN, hs-TNT may be elevated due to marked afterload. Patients with severe HTN and high hs-TNT have higher s.creat values, which are associated with an increased risk of renal failure and in-hospital mortality if their BP decreases acutely to the guideline-target BP. Using biomarkers during the management of emergency HTN should be considered before following clinical guidelines. However, our findings do underscore the potential utility of hs-TNT as an indicator for risk stratification in patients with severe or emergency HTN.
高血压可能导致靶器官损伤(TOD)。在某些情况下,目标血压(BP)管理可能并不合适。
我们旨在评估严重高血压患者中目标 BP 管理对肾 TOD 的影响。
这是一项前瞻性队列研究,涉及因严重高血压(BP > 180/120 且伴有任何症状)而入院的患者。该研究涉及 2017 年 8 月至 2018 年 2 月期间在我们的三级中心转入 ICU 的患者。所有患者均根据最新指南接受目标 BP 治疗。所有患者入院时和 24 小时后均测量高敏肌钙蛋白 T(hs-TNT)和血清肌酐(s.creat)。患者分为 A 组(初始 hs-TNT 正常)和 B 组(初始 hs-TNT 升高)。主要结局是院内肾相关发病率(包括肾功能衰竭)。
共有 470 例高血压危象患者参与研究。B 组的院内死亡率(4 例)和肾 TOD(急性肾功能障碍)发生率明显高于 A 组(P 值分别为 0.001 和 0.000)。B 组入院时的初始 s.creat 与随访 s.creat 值之间存在显著差异,其 s.creat 在接下来的 24 小时内显著升高(P = 0.002),而 A 组无差异(P = 0.34)。hs-TNT 与随访 s.creat 之间存在显著正相关(P = 0.004)。
在严重高血压中,由于明显的后负荷,hs-TNT 可能升高。严重高血压和高 hs-TNT 的患者 s.creat 值较高,如果其 BP 急剧降至指南目标 BP,肾功能衰竭和院内死亡率的风险增加。在遵循临床指南之前,应考虑在紧急处理高血压期间使用生物标志物。然而,我们的研究结果确实强调了 hs-TNT 作为严重或紧急高血压患者风险分层指标的潜在效用。